Get the most recent info and news about Regeneron Pharmaceuticals on HackerNoon, where 10k+ technologists publish stories for 4M+ monthly readers.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals

regeneronpharmaceuticals

The Moderna and Pfizer COVID vaccines were the first to use lipid nanoparticles to deliver mRNA, but difficulties with storage and stability have slowed bringing new therapies based on the biotechnology ... and motivate pharmaceutical industry efforts ...

Purdue engineer works to improve formulation of RNA-based pharmaceuticals

The FDA has signed off on Amgen’s biosimilar version of Johnson & Johnson’s autoimmune standout Stelara. | The FDA has approved Amgen’s biosimilar version of Johnson & Johnson’s autoimmune standout Stelara.

After patent settlement, Amgen scores FDA nod for its biosimilar version of J&J's Stelara

“As leaders of Regeneron, we have avoided wading into areas beyond ... have been within the requisite skill set of those who work in the C-suite of a pharma or biotech company. However, speaking up on controversial social issues is what’s increasingly ...

Pharma CEOs ‘find their voice’ on Israel-Hamas conflict

ETHealthworld.com brings latest healthcare news, views and updates. Get healthcare industry & sector news from all top sources for the Indian Health industry.

Pharma Industry

Moreover, the iShares Biotechnology ETF surged 62 ... It has been the company’s most significant contributor to revenue in 2022—adding $5.8 billion to its bottom line. Regeneron manufactures this drug in partnership with Bayer (BAYRY).

Biotech Stocks To Look Out For in 2023

As sales of their GLP-1 diabetes and obesity drugs have surged, Eli Lilly and Novo Nordisk have become the most valuable biopharma companies in the United States and Europe, respectively. That didn | It was no surprise that GLP-1 drugmakers Eli Lilly and Novo Nordisk saw market-cap gains of 16.

Amgen, Regeneron and AbbVie join Lilly and Novo Nordisk in posting largest Q3 market-cap gains: report

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.

Intellia Therapeutics Will Soon Make Biotech History. Is the Stock a Buy?

The restructuring came as the French company forecast an earnings drop in 2024, prompting a stock selloff that erased about $20 billion in market value.

Sanofi to divest consumer unit, joining pharma industry shift

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hi! Today we see that prime

Regeneron gene therapy improves hearing in child

Begin your TipRanks Premium journey today. Regeneron (REGN) Company Description: Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the ...

Regeneron’s Growth Potential and R&D Conversion: Key Drivers for Buy Rating

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.re generon.com/events-and-presentations. Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days.

Regeneron Announces Investor Conference Presentations

Bank of America is bullish on Eli Lilly (LLY) and Gilead (GILD), and bearish on Pfizer (PFE) and Regeneron (REGN) ahead of biopharma Q3 earnings season. Read more here.

Eli Lilly, Gilead favorites at BofA ahead of Q3 biopharma earnings

In this piece, we will take a look at 12 cheap biotechnology stocks that smart investors are piling into. If you want to skip our introduction to the biotechnology industry and how it might be affected by recent economic and stock market trends,

12 Cheap Biotech Stocks Smart Investors Are Piling Into

Last December, stories started surfacing of a new virus affecting the Chinese city of Wuhan. At the epicenter of the outbreak, Chinese officials started building new hospitals to aid the people in need. What started out as something that looked like a flu epidemic, soon escalated into a full blown pandemic, called the novel coronavirus (SARS-CoV-2). As numbers of infected people are on the rise, the impact on people’s lives continues to grow, beyond anything most of us have ever witnessed in our lives. Social distancing and thorough hand washing seem to be the primary action humans need to abide by in order to slow down the spreading of the virus. On the 19th of March, US President Trump announced three promising drug treatments to battle the coronavirus. Two of them, chloroquine and hydroxychloroquine have been approved by the FDA to start clinical trials on treating the coronavirus. The other is Regeneron, a drug that has previously been used to successfully treat people infected with the Ebola virus. World Health Organization (WHO) Senior Advisor, Bruce Aylward, stated, ‘There’s only one drug right now that we think will have real efficacy, and that’s remdesivir’. Two US companies, and (starting the 23rd of March) have started the process of rolling out home COVID-19 tests. The Nurx one is projected to cost around $181 while Everlywell sells them for $135. The initial supply is low, but they project to be able to scale up manufacturing soon. Nurx will be selling their supply each morning, Monday through Saturday, at 7 AM PST, until stocks run out. Nurx Everlywell I would like to emphasize that I am not an expert in this field, all the information stated in this article is based on reliable sources (official government or national health authorities), field experts like virologists and research papers on the topic. At least until March 20th, there was not yet any proven antidote against the coronavirus. Chloroquine As a medicine used to treat malaria, chloroquine, has been discovered in 1934, , but it had been abandoned for decades as it was too toxic to be prescribed to humans. by Hans Andersag Back in 2004, when the SARS epidemic arose, lab-tested Chloroquine as an anti-virus and it worked. When the time came to test real-life patients the virus had stopped spreading, so there were no people left for clinical trial. Chinese researchers notices quicker recoveries and milder symptoms in COVID19 patients that were given chloroquine. researchers from KU Leuven Researchers of the Rijksuniversiteit Groningen in The Netherlands, are as a means to battle the coronavirus. Paul Hagedoorn and Erik Frijlink from the Rijksuniversiteit are working on cultivating the medicine so it can be used with an inhaler. This way, the medicine is directed straight into the place where it needs to be, the lungs. testing chloroquine and hydroxychloroquine The only manufacturer of chloroquine located in the US (New Jersey), Rising Pharmaceuticals, amidst the increasing amount of people that got infected with the coronavirus. raised the price of chloroquine in January by 100%, Among others, chloroquine producers are located in: , , and . India, China The Netherlands The United States Hydroxychloroquine Hydroxychloroquine, or better known as Plaquenil (brandname), is a working substance used to prevent and treat malaria. It is also widely available to treat auto-immune diseases and rheumatic arthritis. While chloroquine can be highly toxic, an overdose can result in poisoning or death, hydroxychloroquine is about 40% less toxic. A recent , show positive results with patients that were administered hydroxychloroquine as a treatment to COVID-19. The preliminary results look promising, although the trial group was very small (20 patients in the treatment group, 16 in control group). In the treatment group, 6 patients were administered hydroxychloroquine in combination with azithromycin. Within 5 days all 6 patients tested negative on the coronavirus. The treatment group patients that solely received hydroxychloroquine had a 50% decrease in positive testing for COVID-19 after 6 days. Almost 90% of patients in the control group still tested positive for COVID-19 after 6 days. In Tweet, by @AppleHelix you can see the difference between groups very clear. clinical trial, in France this Regeneron and Sanofi Regeneron Pharmaceuticals and Sanofi are working on getting Kevzara approved to be a treatment option for the novel coronavirus. Kevzara is officially a drug that is being used to treat rheumatic arthritis. The clinical trial will research the effect kevzara has on reducing inflammation in the lungs. This isn’t the only COVID-19 related trial they have planned. Scientists at Regeneron are testing on mice that have been genetically modified to have a working human immune system. The company aims to start clinical trials by early summer. The trial consists of a multi-antibody cocktail to be administered to people to treat the coronavirus either before or after infection. Remdesivir In the state of Nebraska, a has started on the 25th of February, using remdesivir as a drug to fight tcoronavirus. Remdesivir, manufactured by , is a broad-spectrum antiviral treatment. Initially they wanted to get the drug approved as a cure to Ebola. clinical trial Gilead Sciences Inc Remdesivir has not been officially approved by any national health organization yet, but the manufacturer is working closely with various organizations to start clinical testing on COVID-19 patients. In the past remdesivir has been successfully tested on rats, as a working antivirus against SARS and MERS infections. According to their website, Gilead Sciences has eight locations in the US. On March 17th remdesivir has been as a drug to treat COVID-19 patients with severe symptoms in the Czech Republic. officially approved Concluding remarks After doing this research, I must say I am surprised by the overall abilities to use existing medicine to treat COVID-19. The research that has been previously done on anti-virus drugs to treat SARS and MERS, can be further built upon with coronavirus patients after approval from the proper authorities. However, most treatments are for faster recovery and/or reducing the symptoms. Besides the four drugs discussed in this articles, there are also other promising anti-virus medicine that are being tested at the moment. In China, COVID-19 patients show positive results after using favipiravir, in a clinical trial. (developed by a subsidiary of Fujifilm) is used in Japan as a treatment against the flu. Patients that took part in the trial recovered sooner from the Coronavirus (after 4 days median, in oppose to 11 days, without favipiravir). Their X-rays also showed improvement in lung conditions with over 90% of clinical trial participants. starts a clinical trial, on a new Coronavirus vaccine, at the end of April. Favipiravir Innovio Pharmaceuticals When I check out the in my home country on how to treat COVID-19, I noticed that patients can request to be treated with Chloroquine, Remdesivir or Hydroxychloroquine, but only if they sign a waiver stating the care givers are not at fault when the patients’ situation decreases. They further state that the drugs have not been tested properly on people with the coronavirus, so it is no official treatment drug yet. country-wide guidelines I hope clinical testing with the previously mentioned drugs will have a positive effect on COVID-19 patients. I applaud national health organizations for stepping up to the plate and working around the clock to get clinical trials approved as soon as possible. Hopefully a drug treatment will be approved and the medicine will be available at a reasonable cost for everyone. Some interesting reads about clinical trail related to treating COVID-19 patients: https://blogs.sciencemag.org/pipeline/archives/2020/03/06/covid-19-small-molecule-therapies-reviewed http://www.chinadaily.com.cn/a/202003/17/WS5e708666a31012821727fcbd.html https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/ Subscribe to my channels , , and if you like my articles and would like to be informed about Blockchain, cryptocurrency projects and news. You can also read my articles on . Steemit Medium Twitter LinkedIn If you have any questions about this article, please comment in the comment section below. Thank you! You can contact me on Telegram @LindaCrypto. LindaCrypto

Stories, News & Mentions about REGENERONPHARMACEUTICALS

Regeneronpharmaceuticals’s Stories on HackerNoon

Regeneronpharmaceuticals's News & Mentions